PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2021.101020225441219-1229Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of ChemotherapyAeran Seol, Ga Won Yim, Joo Yeon Chung, Se Ik Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong Sang Songhttp://e-crt.org/upload/pdf/crt-2021-1010.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2021.1010, http://e-crt.org/upload/pdf/crt-2021-1010.pdf
Ovarian Cancer - From Pathogenesis to Treatment10.5772/intechopen.808902018Chemotherapy for Primary and Recurrent Epithelial Ovarian CancerNora Naqoshttp://www.intechopen.com/download/pdf/63466
Gynecologic Oncology10.1016/j.ygyno.2014.03.3852014133147Multiple lines of chemotherapy in recurrent epithelial ovarian cancer, are more lines better? A decision analytic modelK.M. Esselen, J. Kim, A.W. Wright, N.S. Horowitzhttps://api.elsevier.com/content/article/PII:S0090825814006210?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0090825814006210?httpAccept=text/plain
Gynecologic Oncology10.1016/j.ygyno.2014.04.02420141342431-432Abstract number 6: Multiple lines of chemotherapy in recurrent epithelial ovarian cancer, are more lines better? A decision analytic modelK. Esselen, A. Wright, J. Kim, N. Horowitzhttps://api.elsevier.com/content/article/PII:S0090825814008828?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0090825814008828?httpAccept=text/plain
European Journal of Cancer10.1016/s0959-8049(16)31524-6201551S5502758 Is there a survival benefit for patients who receive post-operative adjuvant chemotherapy following secondary cytoreductive surgery (SCRS) for recurrent epithelial ovarian cancer (EOC)?D. Kolomainen, J. Butler, D. P.J. Barton, A. Taylor, K. Stanley, M. Gore, S. Banerjeehttps://api.elsevier.com/content/article/PII:S0959804916315246?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804916315246?httpAccept=text/plain
Clinical Ovarian Cancer10.3816/coc.2010.n.00620103136-40Do Patients With Platinum-Resistant Epithelial Ovarian Cancer Benefit From Second-line Chemotherapy?Kenji Hashimoto, Noriyuki Katsumata, Taizo Hirata, Kan Yonemori, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Masashi Ando, Yasuhiro Fujiwarahttps://api.elsevier.com/content/article/PII:S1941439011700083?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1941439011700083?httpAccept=text/plain
Cancer Management and Research10.2147/cmar.s2801412020Volume 1211631-11638<p>Is There a Survival Benefit for Patients with Advanced Ovarian Clear Cell Carcinoma Who Complete More Than 6 Cycles of Postoperative Chemotherapy?</p>Jing Wang, Yuying Shi, Yan Liu, Wei Li, Hong Jiang, Hongbing Caihttps://www.dovepress.com/getfile.php?fileID=63736, https://www.dovepress.com/getfile.php?fileID=63736
Gynecologic Oncology10.1016/j.ygyno.2017.03.2382017145101Is there a survival benefit associated with intraperitoneal chemotherapy after neoadjuvant chemotherapy for optimally debulked epithelial ovarian cancer patients?M. Song, R. Isaksson Vogel, C. Rivardhttps://api.elsevier.com/content/article/PII:S0090825817304547?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0090825817304547?httpAccept=text/plain
Clinical Ovarian Cancer10.3816/coc.2008.n.016200812139-140Optimizing Management of Recurrent Epithelial Ovarian Cancer with Non–Platinum-Based ChemotherapyEric Pujade Lauraine, Ignace Vergote, Sandro Pignata, Gunnar Kristensenhttps://api.elsevier.com/content/article/PII:S1941439011700411?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1941439011700411?httpAccept=text/plain
Ovarian Cancer in Elderly Patients10.1007/978-3-319-23588-2_6201663-68Chemotherapy for Recurrent Ovarian Cancer in the Elderly PatientsJean-Emmanuel Kurtz, Laure de Cockhttps://link.springer.com/content/pdf/10.1007/978-3-319-23588-2_6